Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data

Giannis Mountzios, Meletios Athanassios Dimopoulos, Jean Charles Soria, Despina Sanoudou, Christos A. Papadimitriou

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Lung carcinogenesis is considered to be the result of composite environmental, genetic and epigenetic changes. Despite the fact that many of the genetic alterations, including loss of heterozygocity in the 3p chromosome locus and point mutations in the tumor-suppressor genes TP53 and retinoblastoma (RB1), occur in nearly all histopathologic types of lung cancer, the frequency and the " timing" of their occurrence seems to differ between small-cell lung cancer (SCLC) cells, that are characterized by neuroendocrine differentiation, and non-small-cell lung cancer (NSCLC) cells. Although loss of cell-cycle control is the crucial molecular event in both types, the mechanism by which it provokes oncogenesis differs significantly between SCLC and NSCLC. Importantly, some of these molecular events, including DNA-damage response and epidermal growth factor receptor (EGFR) mutations are valuable in predicting response to conventional chemotherapy or molecular-targeted agents as well as in the prognosis of patients that harbor these alterations. In the current review we report on the best characterized histopathologic and genetic changes in NSCLC and SCLC in relation to each histological subtype and we discuss their predictive and prognostic implications.

Original languageEnglish
Pages (from-to)94-109
Number of pages16
JournalCritical Reviews in Oncology/Hematology
Volume75
Issue number2
DOIs
Publication statusPublished - 1 Aug 2010
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Survival
Carcinogenesis
Neuroendocrine Cells
Retinoblastoma
Cell Cycle Checkpoints
Tumor Suppressor Genes
Point Mutation
Epidermal Growth Factor Receptor
Epigenomics
DNA Damage
Therapeutics
Chromosomes
Drug Therapy
Lung
Mutation

Keywords

  • Genetic changes
  • Histopathogenetic changes
  • Lung cancer
  • Non-small-cell lung cancer
  • Predictive value
  • Prognosis
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer : A review of published data. / Mountzios, Giannis; Dimopoulos, Meletios Athanassios; Soria, Jean Charles; Sanoudou, Despina; Papadimitriou, Christos A.

In: Critical Reviews in Oncology/Hematology, Vol. 75, No. 2, 01.08.2010, p. 94-109.

Research output: Contribution to journalArticle

Mountzios, Giannis ; Dimopoulos, Meletios Athanassios ; Soria, Jean Charles ; Sanoudou, Despina ; Papadimitriou, Christos A. / Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer : A review of published data. In: Critical Reviews in Oncology/Hematology. 2010 ; Vol. 75, No. 2. pp. 94-109.
@article{4d2b387b79d3415abf789cdf89273f4d,
title = "Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data",
abstract = "Lung carcinogenesis is considered to be the result of composite environmental, genetic and epigenetic changes. Despite the fact that many of the genetic alterations, including loss of heterozygocity in the 3p chromosome locus and point mutations in the tumor-suppressor genes TP53 and retinoblastoma (RB1), occur in nearly all histopathologic types of lung cancer, the frequency and the {"} timing{"} of their occurrence seems to differ between small-cell lung cancer (SCLC) cells, that are characterized by neuroendocrine differentiation, and non-small-cell lung cancer (NSCLC) cells. Although loss of cell-cycle control is the crucial molecular event in both types, the mechanism by which it provokes oncogenesis differs significantly between SCLC and NSCLC. Importantly, some of these molecular events, including DNA-damage response and epidermal growth factor receptor (EGFR) mutations are valuable in predicting response to conventional chemotherapy or molecular-targeted agents as well as in the prognosis of patients that harbor these alterations. In the current review we report on the best characterized histopathologic and genetic changes in NSCLC and SCLC in relation to each histological subtype and we discuss their predictive and prognostic implications.",
keywords = "Genetic changes, Histopathogenetic changes, Lung cancer, Non-small-cell lung cancer, Predictive value, Prognosis, Small-cell lung cancer",
author = "Giannis Mountzios and Dimopoulos, {Meletios Athanassios} and Soria, {Jean Charles} and Despina Sanoudou and Papadimitriou, {Christos A.}",
year = "2010",
month = "8",
day = "1",
doi = "10.1016/j.critrevonc.2009.10.002",
language = "English",
volume = "75",
pages = "94--109",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer

T2 - A review of published data

AU - Mountzios, Giannis

AU - Dimopoulos, Meletios Athanassios

AU - Soria, Jean Charles

AU - Sanoudou, Despina

AU - Papadimitriou, Christos A.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Lung carcinogenesis is considered to be the result of composite environmental, genetic and epigenetic changes. Despite the fact that many of the genetic alterations, including loss of heterozygocity in the 3p chromosome locus and point mutations in the tumor-suppressor genes TP53 and retinoblastoma (RB1), occur in nearly all histopathologic types of lung cancer, the frequency and the " timing" of their occurrence seems to differ between small-cell lung cancer (SCLC) cells, that are characterized by neuroendocrine differentiation, and non-small-cell lung cancer (NSCLC) cells. Although loss of cell-cycle control is the crucial molecular event in both types, the mechanism by which it provokes oncogenesis differs significantly between SCLC and NSCLC. Importantly, some of these molecular events, including DNA-damage response and epidermal growth factor receptor (EGFR) mutations are valuable in predicting response to conventional chemotherapy or molecular-targeted agents as well as in the prognosis of patients that harbor these alterations. In the current review we report on the best characterized histopathologic and genetic changes in NSCLC and SCLC in relation to each histological subtype and we discuss their predictive and prognostic implications.

AB - Lung carcinogenesis is considered to be the result of composite environmental, genetic and epigenetic changes. Despite the fact that many of the genetic alterations, including loss of heterozygocity in the 3p chromosome locus and point mutations in the tumor-suppressor genes TP53 and retinoblastoma (RB1), occur in nearly all histopathologic types of lung cancer, the frequency and the " timing" of their occurrence seems to differ between small-cell lung cancer (SCLC) cells, that are characterized by neuroendocrine differentiation, and non-small-cell lung cancer (NSCLC) cells. Although loss of cell-cycle control is the crucial molecular event in both types, the mechanism by which it provokes oncogenesis differs significantly between SCLC and NSCLC. Importantly, some of these molecular events, including DNA-damage response and epidermal growth factor receptor (EGFR) mutations are valuable in predicting response to conventional chemotherapy or molecular-targeted agents as well as in the prognosis of patients that harbor these alterations. In the current review we report on the best characterized histopathologic and genetic changes in NSCLC and SCLC in relation to each histological subtype and we discuss their predictive and prognostic implications.

KW - Genetic changes

KW - Histopathogenetic changes

KW - Lung cancer

KW - Non-small-cell lung cancer

KW - Predictive value

KW - Prognosis

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=77955052650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955052650&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2009.10.002

DO - 10.1016/j.critrevonc.2009.10.002

M3 - Article

C2 - 19914087

AN - SCOPUS:77955052650

VL - 75

SP - 94

EP - 109

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -